Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Thiazolidinediones398 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00034 | 35249505 | Curr Drug Saf | Pioglitazone, Bladder Cancer and the Presumption of Innocence. | 2022 | Details |
| A00475 | 35068786 | J Clin Exp Hepatol | Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study. | 2021 | Details |
| A00656 | 35013417 | Sci Rep | Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver. | 2022 | Details |
| A00724 | 34988690 | Acta Diabetol | Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. | 2022 | Details |
| A01118 | 34863942 | Mol Metab | The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease. | 2021 | Details |
| A01673 | 34659439 | Evid Based Complement Alternat Med | Ginsenoside Re Improves Inflammation and Fibrosis in Hepatic Tissue by Upregulating PPARγ Expression and Inhibiting Oxidative Stress in db/db Mice. | 2021 | Details |
| A01741 | 34630909 | World J Diabetes | Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. | 2021 | Details |
| A01808 | 34607257 | Biochem Biophys Res Commun | The alleviating effect of sphingosine kinases 2 inhibitor K145 on nonalcoholic fatty liver. | 2021 | Details |
| A01948 | 34557367 | Cureus | Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus. | 2021 | Details |
| A02326 | 34417811 | Endocrinology | Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity. | 2021 | Details |
| A02850 | 34219361 | Liver Int | PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. | 2021 | Details |
| A03104 | 34129693 | Hepatology | Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. | 2021 | Details |
| A03385 | 34022222 | J Biol Chem | Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. | 2021 | Details |
| A03626 | 33925827 | Int J Mol Sci | Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. | 2021 | Details |
| A03740 | 33882758 | Expert Rev Clin Pharmacol | Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. | 2021 | Details |
| A03861 | 33841337 | Front Endocrinol (Lausanne) | Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis. | 2021 | Details |
| A03995 | 33798599 | Eur J Pharmacol | Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH. | 2021 | Details |
| A04068 | 33771699 | Pharmacol Res | Epigenetics in NAFLD/NASH: Targets and therapy. | 2021 | Details |
| A04933 | 33444819 | Cell Mol Gastroenterol Hepatol | Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver. | 2021 | Details |
| A05137 | 33359401 | Mol Metab | Insulin resistance is mechanistically linked to hepatic mitochondrial remodeling in non-alcoholic fatty liver disease. | 2020 | Details |
| A05637 | 33179890 | Am Fam Physician | Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management. | 2020 | Details |
| A06316 | 32932174 | J Trace Elem Med Biol | The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. | 2020 | Details |
| A06520 | 32843283 | J Diabetes Complications | Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. | 2020 | Details |
| A07111 | 32619031 | Diabet Med | Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. | 2020 | Details |
| A07128 | 32610115 | J Hepatol | Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. | 2020 | Details |
| A08327 | 32151660 | Metabolism | Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. | 2020 | Details |
| A08963 | 31923578 | Diabetes Metab | Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. | 2020 | Details |
| A09046 | 31889755 | J Clin Exp Hepatol | Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09415 | 31757735 | Presse Med | [Pharmacological treatment of NASH]. | 2019 | Details |
| A09548 | 31697972 | J Hepatol | Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. | 2019 | Details |
| A10678 | 31239664 | Int J Nanomedicine | Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis. | 2019 | Details |
| A10728 | 31219486 | Saudi Med J | Position statement on the diagnosis and management of non-alcoholic fatty liver disease. | 2019 | Details |
| A11018 | 31080822 | Biomed Res Int | Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis. | 2019 | Details |
| A11553 | 30844893 | Curr Opin Gastroenterol | Current treatment options for nonalcoholic fatty liver disease. | 2019 | Details |
| A11905 | 30686780 | Cell Mol Gastroenterol Hepatol | Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism. | 2018 | Details |
| A12137 | 30588181 | Int J Med Sci | Phenotypic Alteration of Hepatocytes in Non-Alcoholic Fatty Liver Disease. | 2018 | Details |
| A12209 | 30561132 | Basic Clin Pharmacol Toxicol | A role of peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease. | 2019 | Details |
| A12514 | 30413050 | Pharmaceuticals (Basel) | Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? | 2018 | Details |
| A12660 | 30341231 | Postgrad Med J | Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. | 2018 | Details |
| A12765 | 30298052 | Front Endocrinol (Lausanne) | The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition. | 2018 | Details |
| A12801 | 30282916 | Diseases | Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. | 2018 | Details |
| A13247 | 30065651 | Front Pharmacol | A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis. | 2018 | Details |
| A13383 | 30008738 | PPAR Res | Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice. | 2018 | Details |
| A13493 | 29950116 | Expert Opin Investig Drugs | MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis. | 2018 | Details |
| A13643 | 29858843 | Hormones (Athens) | The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). | 2018 | Details |
| A13975 | 29662003 | Int J Mol Sci | PPAR Agonists and Metabolic Syndrome: An Established Role? | 2018 | Details |
| A13990 | 29655574 | Rev Gastroenterol Mex (Engl Ed) | Current treatment for non-alcoholic fatty liver disease. | 2018 | Details |
| A14003 | 29643297 | J Vet Med Sci | Investigation of pharmacological responses to anti-diabetic drugs in female Spontaneously Diabetic Torii (SDT) fatty rats, a new nonalcoholic steatohepatitis (NASH) model. | 2018 | Details |
| A14097 | 29589386 | Endocrinol Metab (Seoul) | Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A14177 | 29550470 | Biochem Biophys Res Commun | PPARγ alleviated hepatocyte steatosis through reducing SOCS3 by inhibiting JAK2/STAT3 pathway. | 2018 | Details |
| A14394 | 29428719 | Biochem Biophys Res Commun | Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. | 2018 | Details |
| A14400 | 29427492 | Liver Int | Future therapy for non-alcoholic fatty liver disease. | 2018 | Details |
| A14424 | 29413959 | Redox Biol | Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. | 2018 | Details |
| A14576 | 29344336 | Ther Adv Endocrinol Metab | Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. | 2017 | Details |
| A14808 | 29223443 | Clin Gastroenterol Hepatol | Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. | 2017 | Details |
| A14978 | 29146119 | Diabetes Res Clin Pract | An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. | 2017 | Details |
| A15014 | 29128055 | Clin Liver Dis | Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. | 2017 | Details |
| A15082 | 29106066 | J Dig Dis | Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence. | 2017 | Details |
| A15254 | 29023319 | Eur J Gastroenterol Hepatol | Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. | 2017 | Details |
| A15361 | 28946547 | Cancer Biomark | Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study. | 2017 | Details |
| A15703 | 28751548 | Diabetes Care | Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. | 2017 | Details |
| A15798 | 28705172 | BMC Endocr Disord | Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. | 2017 | Details |
| A15862 | 28677333 | Aliment Pharmacol Ther | Review article: new treatments in non-alcoholic fatty liver disease. | 2017 | Details |
| A16016 | 28611274 | Ann Hepatol | Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. | 2018 | Details |
| A16076 | 28581362 | Future Cardiol | PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ. | 2017 | Details |
| A16092 | 28575232 | J Clin Endocrinol Metab | Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. | 2017 | Details |
| A16175 | 28521870 | Metabolism | The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. | 2017 | Details |
| A16234 | 28494529 | Clin Mol Hepatol | NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. | 2017 | Details |
| A16288 | 28470881 | Aliment Pharmacol Ther | Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis. | 2017 | Details |
| A16325 | 28458350 | Biol Pharm Bull | Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation. | 2017 | Details |
| A16488 | 28358980 | Cochrane Database Syst Rev | Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. | 2017 | Details |
| A16515 | 28346237 | Curr Opin Gastroenterol | Current and future pharmacologic treatment of nonalcoholic steatohepatitis. | 2017 | Details |
| A16692 | 28241279 | JAMA Intern Med | Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. | 2017 | Details |
| A16774 | 28185715 | Clin Ther | Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. | 2017 | Details |
| A16925 | 28089623 | Dig Liver Dis | Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? | 2016 | Details |
| A17004 | 28052626 | Liver Int | Therapies in non-alcoholic steatohepatitis (NASH). | 2017 | Details |
| A17053 | 28027586 | Hepatology | Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. | 2017 | Details |
| A17081 | 28001263 | Rev Assoc Med Bras (1992) | Current management of non-alcoholic fatty liver disease. | 2016 | Details |
| A17111 | 27986466 | Trends Endocrinol Metab | Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. | 2016 | Details |
| A17202 | 27916647 | Biochimie | PPARs and nonalcoholic fatty liver disease. | 2016 | Details |
| A17207 | 27914133 | J Korean Med Sci | Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness. | 2017 | Details |
| A17364 | 27823604 | Endocrinol Metab Clin North Am | Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. | 2016 | Details |
| A17395 | 27729660 | Nat Rev Gastroenterol Hepatol | NAFLD and diabetes mellitus. | 2016 | Details |
| A17409 | 27797398 | Eur J Clin Invest | Hepatic chemerin mRNA expression is reduced in human nonalcoholic steatohepatitis. | 2016 | Details |
| A17519 | 27759627 | Medicine (Baltimore) | Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials. | 2016 | Details |
| A17595 | 27727520 | Liver Int | The therapeutic landscape of non-alcoholic steatohepatitis. | 2016 | Details |
| A17814 | 27564402 | Expert Opin Pharmacother | Emerging and future therapies for nonalcoholic steatohepatitis in adults. | 2016 | Details |
| A17839 | 27545964 | Sci Rep | Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice. | 2016 | Details |
| A17856 | 27522101 | Drug Metab Pers Ther | Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease. | 2016 | Details |
| A17870 | 27512874 | Medicine (Baltimore) | Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. | 2016 | Details |
| A17878 | 27506737 | Metabolism | Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. | 2016 | Details |
| A17954 | 27456668 | Drug Metab Lett | UHPLC Quantitation Method for New Thiazolidinedione LPSF/GQ-02 and In Vitro/In Vivo Kinetic Studies. | 2016 | Details |
| A18105 | 27349145 | Eur J Pharmacol | Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD). | 2016 | Details |
| A18144 | 27322798 | Ann Intern Med | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. | 2016 | Details |
| A18220 | 27277347 | Mymensingh Med J | Comparative Study between Pentoxifylline and Pioglitazone in the Treatment of Non-Alcoholic Fatty Liver Disease among Newly Detected Glucose Intolerant Patients. | 2016 | Details |
| A18317 | 27216550 | J Cell Physiol | Association Between Aerobic Exercise and Rosiglitazone Avoided the NAFLD and Liver Inflammation Exacerbated in PPAR-α Knockout Mice. | 2016 | Details |
| A18452 | 27125895 | AAPS J | Dual Outcomes of Rosiglitazone Treatment on Fatty Liver. | 2016 | Details |
| A18484 | 27101131 | Diabetologia | Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. | 2016 | Details |
| A18539 | 27063274 | Clin Liver Dis | Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A18741 | 26976710 | Endocrinol Nutr | Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. | 2016 | Details |